|
Revenue - Additional Information (Detail)
|
3 Months Ended | 9 Months Ended | 1 Months Ended | 3 Months Ended | 9 Months Ended | 1 Months Ended | 3 Months Ended | 9 Months Ended | 1 Months Ended | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 30, 2013
USD ($)
|
Sep. 30, 2014
USD ($)
|
Sep. 30, 2014
RUB
|
Sep. 30, 2013
USD ($)
|
Sep. 30, 2013
RUB
|
Dec. 31, 2013
Amgen, Inc. [Member]
|
Jan. 31, 2013
Amgen, Inc. [Member]
USD ($)
|
Sep. 30, 2014
Amgen, Inc. [Member]
USD ($)
|
Jun. 30, 2014
Amgen, Inc. [Member]
USD ($)
|
Sep. 30, 2013
Amgen, Inc. [Member]
USD ($)
|
Sep. 30, 2014
Amgen, Inc. [Member]
USD ($)
|
Sep. 30, 2013
Amgen, Inc. [Member]
USD ($)
|
Mar. 31, 2013
Pfizer Inc. [Member]
USD ($)
Option
|
Sep. 30, 2014
Pfizer Inc. [Member]
USD ($)
|
Sep. 30, 2013
Pfizer Inc. [Member]
USD ($)
|
Sep. 30, 2014
Pfizer Inc. [Member]
USD ($)
|
Sep. 30, 2013
Pfizer Inc. [Member]
USD ($)
|
Apr. 30, 2013
AstraZeneca AB [Member]
USD ($)
|
Sep. 30, 2014
AstraZeneca AB [Member]
USD ($)
|
Sep. 30, 2013
AstraZeneca AB [Member]
USD ($)
|
Sep. 30, 2014
AstraZeneca AB [Member]
USD ($)
|
Sep. 30, 2013
AstraZeneca AB [Member]
USD ($)
|
Sep. 30, 2014
Ministry of Industry and Trade of Russian Federation [Member]
Russia [Member]
USD ($)
|
Sep. 30, 2013
Ministry of Industry and Trade of Russian Federation [Member]
Russia [Member]
USD ($)
|
Sep. 30, 2014
Ministry of Industry and Trade of Russian Federation [Member]
Russia [Member]
USD ($)
|
Sep. 30, 2013
Ministry of Industry and Trade of Russian Federation [Member]
Russia [Member]
USD ($)
|
Sep. 30, 2014
F. Hoffmann-La Roche Ltd [Member]
USD ($)
|
Sep. 30, 2014
F. Hoffmann-La Roche Ltd [Member]
USD ($)
|
|
| Revenues [Line Items] | ||||||||||||||||||||||||||||
| Total revenue | $ 600,000 | 22,300,000 | $ 600,000 | 19,900,000 | ||||||||||||||||||||||||
| Contract amount recognized | 151,000 | 418,000 | 516,000 | 0 | 200,000 | 400,000 | 500,000 | |||||||||||||||||||||
| Company recognized amount related to the research, option and license agreement | 0 | 1,600,000 | 800,000 | 3,900,000 | 300,000 | 1,400,000 | 400,000 | 2,100,000 | 2,800,000 | 1,300,000 | 5,500,000 | 1,900,000 | 300,000 | 300,000 | ||||||||||||||
| Company received upfront payment | 5,000,000 | 800,000 | 4,000,000 | 4,000,000 | ||||||||||||||||||||||||
| Total contingent payments | 89,500,000 | 193,000,000 | ||||||||||||||||||||||||||
| Company granted option | 2 | |||||||||||||||||||||||||||
| Agreement expiration period | 2015-09 | |||||||||||||||||||||||||||
| Additional contingent payments | $ 110,000,000 | |||||||||||||||||||||||||||
| Option exercise period | 9 months | |||||||||||||||||||||||||||
| Reduction in net loss per share, basic and diluted | $ 0.05 | |||||||||||||||||||||||||||